AEON Biopharma Presents Data Showing ABP-450 Matches BOTOX® Structure and Function
Event summary
- AEON Biopharma presented data at the 68th Annual Scientific Meeting of the American Headache Society demonstrating structural and functional comparability of ABP-450 to BOTOX®.
- The data included genomic sequence alignment, LC-MS peptide mapping, and LD50 potency assay results, showing 93%-99% sequence coverage and functional similarity within predefined equivalence criteria.
- ABP-450 is a biosimilar to BOTOX®, targeting the $3.0 billion annual U.S. therapeutic neurotoxin market.
- The presentation was made by Chad K. Oh, M.D., AEON's Chief Medical Officer, on June 4, 2026.
The big picture
AEON Biopharma's presentation at the American Headache Society meeting underscores its strategy to disrupt the $3.0 billion U.S. therapeutic neurotoxin market with a biosimilar to BOTOX®. The data supports ABP-450's potential to achieve full-label market entry, challenging Allergan's dominance in chronic migraine treatment. The success of this strategy hinges on regulatory approval and competitive positioning against established players like Evolus, Inc.
What we're watching
- Regulatory Pathway
- How AEON Biopharma will leverage this data to advance ABP-450 through the FDA approval process for full-label therapeutic use.
- Market Competition
- Whether ABP-450 can gain market share against BOTOX® in the chronic migraine treatment segment.
- Execution Risk
- The pace at which AEON Biopharma can secure regulatory approvals and commercialize ABP-450 in key markets.